



COMPANY OVERVIEW

Synthetic Biologics is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. Our lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). We are also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).

RECENT NEWS

Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018

Feb 15 2018, 4:10 PM EST

STOCK OVERVIEW

Symbol	SYN
Exchange	NYSE American
Shares OS	128,566,883
Market Cap	\$53.36M
Last Price	\$0.415
52-Week Range	\$0.37 - \$1.05

INVESTOR RELATIONS

Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364
info@syntheticbiologics.com

MANAGEMENT TEAM

Steven Shallcross

Interim CEO, Chief Financial Officer,
Treasurer and Secretary

Joseph Sliman, MD, MPH

Chief Medical Officer

Michael Kaleko, MD, PhD

Senior Vice President, Research &
Development

Raymond D. Stapleton, Jr., PhD

Senior Vice President, Manufacturing

Deb Mathews, PharmD

Vice President, Medical Affairs

SYNTHETIC BIOLOGICS, INC.

9605 Medical Center Drive
Suite 270
Rockville, MD 20850
US
T: (301) 417-4364
<https://www.syntheticbiologics.com>

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in the Company's industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements.